Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Targets for AD treatment: conflicting messages from γ-secretase inhibitors.

Sambamurti K, Greig NH, Utsuki T, Barnwell EL, Sharma E, Mazell C, Bhat NR, Kindy MS, Lahiri DK, Pappolla MA.

J Neurochem. 2011 May;117(3):359-74. doi: 10.1111/j.1471-4159.2011.07213.x. Epub 2011 Mar 15.

2.

Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.

Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Logroscino G, Santamato A, Greco A, Seripa D, Pilotto A.

Curr Med Chem. 2011;18(35):5430-47. Review.

PMID:
22087836
3.

γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.

Imbimbo BP, Giardina GA.

Curr Top Med Chem. 2011;11(12):1555-70. Review.

PMID:
21510832
4.

Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.

D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A.

Expert Opin Drug Discov. 2012 Jan;7(1):19-37. doi: 10.1517/17460441.2012.645534. Epub 2011 Dec 14. Review.

PMID:
22468891
5.

Therapeutic intervention for Alzheimer's disease with γ-secretase inhibitors: still a viable option?

Imbimbo BP, Panza F, Frisardi V, Solfrizzi V, D'Onofrio G, Logroscino G, Seripa D, Pilotto A.

Expert Opin Investig Drugs. 2011 Mar;20(3):325-41. doi: 10.1517/13543784.2011.550572. Epub 2011 Jan 11. Review.

PMID:
21222550
6.

Modulation of γ-secretase activity by multiple enzyme-substrate interactions: implications in pathogenesis of Alzheimer's disease.

Svedružić ZM, Popović K, Smoljan I, Sendula-Jengić V.

PLoS One. 2012;7(3):e32293. doi: 10.1371/journal.pone.0032293. Epub 2012 Mar 30.

7.

Therapeutic potential of gamma-secretase inhibitors and modulators.

Imbimbo BP.

Curr Top Med Chem. 2008;8(1):54-61. Review.

PMID:
18220933
8.

A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis.

Sambamurti K, Suram A, Venugopal C, Prakasam A, Zhou Y, Lahiri DK, Greig NH.

Curr Alzheimer Res. 2006 Feb;3(1):81-90. Review.

PMID:
16472208
9.

REVIEW: γ-Secretase inhibitors for the treatment of Alzheimer's disease: The current state.

Panza F, Frisardi V, Imbimbo BP, Capurso C, Logroscino G, Sancarlo D, Seripa D, Vendemiale G, Pilotto A, Solfrizzi V.

CNS Neurosci Ther. 2010 Oct;16(5):272-84. doi: 10.1111/j.1755-5949.2010.00164.x. Epub 2010 Jun 16. Review.

PMID:
20560993
10.

Inhibition and modulation of gamma-secretase for Alzheimer's disease.

Wolfe MS.

Neurotherapeutics. 2008 Jul;5(3):391-8. doi: 10.1016/j.nurt.2008.05.010. Review.

11.

Gamma-secretase inhibition and modulation for Alzheimer's disease.

Wolfe MS.

Curr Alzheimer Res. 2008 Apr;5(2):158-64. Review.

12.
13.

γ-secretase substrates and their implications for drug development in Alzheimer's disease.

Lleó A, Saura CA.

Curr Top Med Chem. 2011;11(12):1513-27. Review.

PMID:
21510835
14.

gamma-Secretase as a therapeutic target in Alzheimer's disease.

Guardia-Laguarta C, Pera M, Lleó A.

Curr Drug Targets. 2010 Apr;11(4):506-17. Review.

PMID:
20015011
15.

gamma-secretase as a therapeutic target for treatment of Alzheimer's disease.

Tomita T, Iwatsubo T.

Curr Pharm Des. 2006;12(6):661-70. Review.

PMID:
16472155
16.

Inhibition of γ-secretase worsens memory deficits in a genetically congruous mouse model of Danish dementia.

Tamayev R, D'Adamio L.

Mol Neurodegener. 2012 Apr 26;7:19. doi: 10.1186/1750-1326-7-19.

17.

Pharmacological evidences for DFK167-sensitive presenilin-independent gamma-secretase-like activity.

Sevalle J, Ayral E, Hernandez JF, Martinez J, Checler F.

J Neurochem. 2009 Jul;110(1):275-83. doi: 10.1111/j.1471-4159.2009.06131.x. Epub 2009 Apr 29.

18.

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF.

Drugs R D. 2006;7(2):87-97. Review.

PMID:
16542055
19.

Cell signaling abnormalities may drive neurodegeneration in familial Alzheimer disease.

Robakis NK.

Neurochem Res. 2014;39(3):570-5. doi: 10.1007/s11064-013-1003-6. Epub 2013 Feb 23. Review.

20.

Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.

Strömberg K, Eketjäll S, Georgievska B, Tunblad K, Eliason K, Olsson F, Radesäter AC, Klintenberg R, Arvidsson PI, von Berg S, Fälting J, Cowburn RF, Dabrowski M.

FEBS J. 2015 Jan;282(1):65-73. doi: 10.1111/febs.13103. Epub 2014 Nov 7.

Supplemental Content

Support Center